No current peripheral neuropathy > grade 2 at time of randomizationXx_NEWLINE_xXGrade 2 or greater peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy Grade ? 2Xx_NEWLINE_xXPeripheral neuropathy of any etiology that exceeds grade 1Xx_NEWLINE_xXPatients must not have baseline peripheral neuropathy that exceeds grade 1Xx_NEWLINE_xXGrade >= 2 neuropathyXx_NEWLINE_xX=< grade 2 peripheral neuropathy; patients with grade 1 peripheral neuropathy with pain will be excludedXx_NEWLINE_xXNo grade 2 or higher neuropathyXx_NEWLINE_xX=< grade 2 peripheral neuropathyXx_NEWLINE_xXRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): =< grade 2 peripheral neuropathyXx_NEWLINE_xXPresence of grade > 2 peripheral neuropathy or patients with the demyelinating form of Charcot-Marie-Tooth syndromeXx_NEWLINE_xXIf applicable, patient with >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXPeripheral neuropathy >= 2Xx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXNeuropathy, grade 2 or greater by NCI-CTCAE, v 4.0Xx_NEWLINE_xXPatients with grade 2 or higher peripheral neuropathy will be excluded in the dose escalation phase of the protocolXx_NEWLINE_xXPatients with a baseline peripheral neuropathy >= grade 2 will not be eligibleXx_NEWLINE_xXPatients with preexisting grade II peripheral neuropathyXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not have grade 3 or higher peripheral neuropathyXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE II (ARM D): Patients must not have grade 3 or higher peripheral neuropathyXx_NEWLINE_xXBaseline neuropathy of > grade 2Xx_NEWLINE_xXPeripheral neuropathy ? Grade 2.Xx_NEWLINE_xXPatients with peripheral neuropathy of grade 2 or higherXx_NEWLINE_xXGrade >= 2 peripheral neuropathy at the present timeXx_NEWLINE_xXPeripheral neuropathy of Grade 2 within 3 weeks prior to the first study therapyXx_NEWLINE_xXSAFETY RUN-IN: Patients with baseline grade 2 neuropathyXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Patients with baseline grade 2 neuropathyXx_NEWLINE_xXPeripheral neuropathy ?grade 3.Xx_NEWLINE_xX>= grade 3 neuropathy at the time of enrollmentXx_NEWLINE_xXGrade 2 or greater peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2 at screeningXx_NEWLINE_xXSubjects with pre-existing grade II peripheral neuropathyXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade less than or equal to (<=) 1, except alopecia (any grade) and Grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy > Grade 2 despite supportive therapy.Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPatients who have >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening period are not eligibleXx_NEWLINE_xXG>1 pre-existing peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy of severity greater than grade 1Xx_NEWLINE_xXGrade 2 or higher peripheral neuropathy at screeningXx_NEWLINE_xXNeuropathy > grade 1Xx_NEWLINE_xXSignificant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollmentXx_NEWLINE_xXSignificant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before enrollmentXx_NEWLINE_xXPeripheral neuropathy greater than or equal to Grade 2Xx_NEWLINE_xXParticipants with >= grade 2 peripheral neuropathyXx_NEWLINE_xXClinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01Xx_NEWLINE_xXPre-existing peripheral neuropathy Grade 2 or higherXx_NEWLINE_xXBaseline peripheral neuropathy of severity > grade 1Xx_NEWLINE_xXGrade 2 to 4 peripheral neuropathy (NCI CTCAE v 4.03).Xx_NEWLINE_xXPatient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPresence of >= grade 2 peripheral neuropathyXx_NEWLINE_xXCTCAE Grade > 2 neuropathyXx_NEWLINE_xXBaseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndromeXx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXPresence of peripheral neuropathy > grade 1Xx_NEWLINE_xXGrade 2 or higher peripheral neuropathy or ataxia per NCI CTCAEXx_NEWLINE_xXPeripheral neuropathy =< grade 1 at the time of registrationXx_NEWLINE_xXPre-existing neuropathy Grade 2 or higherXx_NEWLINE_xXNeurosensory neuropathy > grade 2 at baseline.Xx_NEWLINE_xXPresence of > grade 1 peripheral neuropathyXx_NEWLINE_xXNeuropathy ? Grade 2.Xx_NEWLINE_xXGrade 2 peripheral neuropathy or higher or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathy >Grade 2Xx_NEWLINE_xXPatients must not have peripheral neuropathy ? grade 2Xx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy or neuropathy with pain, regardless of grade that is seen on clinical examination during the screening periodXx_NEWLINE_xXPatients with a history of grade >= 2 neuropathyXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy > grade 1Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to (<=) 1, except alopecia (any grade) and Grade 2 peripheral neuropathyXx_NEWLINE_xXPatients with greater than or equal to grade 2 peripheral neuropathy or active herpes infectionXx_NEWLINE_xXPeripheral neuropathy > CTCAE grade 1Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPatients with >= grade 2 neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening periodXx_NEWLINE_xXSignificant neuropathy > grade 2 at the time of first dose or within 14 days of enrollmentXx_NEWLINE_xXNeuropathy > grade 1Xx_NEWLINE_xX< Grade 2 pre-existing peripheral neuropathy per CTCAEXx_NEWLINE_xXPeripheral neuropathy ? grade 3 on clinical examination or grade 2 with pain during the screening periodXx_NEWLINE_xXPeripheral neuropathy > grade 2 or > grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXClinically significant (>= grade 2) peripheral neuropathy at the time of study entryXx_NEWLINE_xXPatients with grade 2 or higher neuropathyXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade less than or equal to 1, except alopecia (any grade) and grade 2 peripheral neuropathyXx_NEWLINE_xXPatients must not have Grade 2 or higher peripheral neuropathy.Xx_NEWLINE_xXPatients with pre-existing grade >= 3 peripheral neuropathyXx_NEWLINE_xXToxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathyXx_NEWLINE_xXPatients with pre-existing peripheral neuropathy that would limit treatment with taxanes and platinum agentsXx_NEWLINE_xXPeripheral neuropathy grade > 1Xx_NEWLINE_xXPeripheral neuropathy > grade 1, except for grade 2 without limitations on instrumental daily life activities;Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXHave Grade 3 or 4 peripheral neuropathy per NCI-CTCAE Version 4.0.Xx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to screeningXx_NEWLINE_xXExclude patients with pre-existing neuropathy grade 2 or higherXx_NEWLINE_xXPatients with grade 2 or greater neuropathyXx_NEWLINE_xXHas greater than Grade 1 peripheral sensory neuropathy or > Grade 1 peripheral motor neuropathy graded according to the Modified (\Balis\) Pediatric Scale of Peripheral Neuropathies.Xx_NEWLINE_xXPatients must have < grade 2 pre-existing peripheral neuropathy (per CTCAE)Xx_NEWLINE_xXCTCAE grade >= 2 peripheral neuropathy is NOT permittedXx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain) within 21 days prior to registrationXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXEffects of any other prior therapies not reverted to ? Grade 1 (or ? Grade 2 for alopecia and peripheral neuropathy).Xx_NEWLINE_xXPre-existing peripheral neuropathy of grade II or higherXx_NEWLINE_xXGrade 3 peripheral neuropathy within 14 days before enrollment.Xx_NEWLINE_xXPeripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of any cause on clinical examination during the Screening period.Xx_NEWLINE_xXToxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathyXx_NEWLINE_xXActive >= grade 3 peripheral neuropathyXx_NEWLINE_xXGrade 2 or greater neuropathyXx_NEWLINE_xXPatients with any baseline grade 2 neuropathyXx_NEWLINE_xXEvidence of peripheral neuropathy > grade 1 by NCI-CTCAE version 4.03;Xx_NEWLINE_xXPeripheral neuropathy > grade 1Xx_NEWLINE_xXPatients with > grade 1 peripheral neuropathyXx_NEWLINE_xXPre-existing grade 3 or 4 neuropathyXx_NEWLINE_xXPeripheral neuropathy grade 1 or less.Xx_NEWLINE_xXGrade 3 baseline neuropathyXx_NEWLINE_xXCurrent Grade greater than (>) 1 peripheral neuropathy by clinical examinationXx_NEWLINE_xXNeuropathy: patients must have =< grade 1 neuropathy at enrollmentXx_NEWLINE_xXNo peripheral neuropathyXx_NEWLINE_xXBaseline grade II peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening periodXx_NEWLINE_xXCurrent peripheral neuropathy >= grade 2Xx_NEWLINE_xXPeripheral neuropathy >= grade 2 at screeningXx_NEWLINE_xXPatient has greater than or equal than grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathy grade 2 or greaterXx_NEWLINE_xXPatients with a peripheral neuropathy > grade 1Xx_NEWLINE_xXNeuropathy =< grade 1 at the time of registrationXx_NEWLINE_xXDiabetic neuropathy (any grade)Xx_NEWLINE_xXParticipants with baseline peripheral neuropathy greater than grade 2Xx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to grade =< 1, except alopecia (any grade) and < grade 2 peripheral neuropathyXx_NEWLINE_xXNeuropathy grade >1Xx_NEWLINE_xXPre-existing neuropathy greater than grade 1Xx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXBaseline grade II peripheral neuropathyXx_NEWLINE_xXGrade 3 or higher peripheral neuropathyXx_NEWLINE_xXPatients with greater than or equal to grade 2 peripheral neuropathy at baselineXx_NEWLINE_xXSignificant neuropathy (grades 2 or grade 1 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXGrade 2 or greater neuropathyXx_NEWLINE_xXNo symptoms attributable to grade 2 or higher peripheral neuropathyXx_NEWLINE_xXPatients with grade 2 or higher peripheral neuropathy are excludedXx_NEWLINE_xXNeuropathy >= grade 1Xx_NEWLINE_xXPatient has baseline neuropathy of >= grade 2Xx_NEWLINE_xXPatients with a peripheral neuropathy > grade 1Xx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Peripheral neuropathy >= grade 2Xx_NEWLINE_xXHave grade 2 or greater neuropathy at the time of screeningXx_NEWLINE_xXCTCAE grade 3 or higher peripheral neuropathyXx_NEWLINE_xXGrade >= 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPre-existing peripheral neuropathy of severity grade >= 2 (limiting instrumental activities of daily living)Xx_NEWLINE_xXSignificant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPatient has ? grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xX> Grade 1 peripheral neuropathy within 14 days before enrollment.Xx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXCurrent grade 2 or higher peripheral neuropathyXx_NEWLINE_xXUncontrolled neuropathy grade 2 or greater, regardless of causeXx_NEWLINE_xXPre-existing neuropathy of >= grade 2Xx_NEWLINE_xXGrade >= 2 peripheral neuropathy at baseline (within 21 days prior to cycle 1 day 1)Xx_NEWLINE_xXPatients with peripheral neuropathy of > grade 1Xx_NEWLINE_xXNo peripheral edema >= grade 2 at baselineXx_NEWLINE_xXNo peripheral neuropathy >= grade 2 at baselineXx_NEWLINE_xXNo prior evidence of grade 3 or greater ototoxicity or neuropathyXx_NEWLINE_xXGrade 2 or higher peripheral neuropathy.Xx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain)Xx_NEWLINE_xXNeurological assessment for pre-existing peripheral neuropathyXx_NEWLINE_xXMust not have any significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to enrollment.Xx_NEWLINE_xXSignificant neuropathy (grades 3 to 4 or grade 2 pain)Xx_NEWLINE_xXPeripheral neuropathy, if present, should be =< grade 1Xx_NEWLINE_xXSignificant neuropathy (grade 3, grade 4) at the time of the first dose and/or within 14 days before enrollmentXx_NEWLINE_xXPeripheral neuropathy > grade 1 if due to brentuximab vedotin or any peripheral neuropathy > grade 2Xx_NEWLINE_xXPeripheral neuropathy grade 0-2Xx_NEWLINE_xXRecovery of all chemotherapy or radiation-related toxicities to grade =< 1, except for alopecia and peripheral neuropathyXx_NEWLINE_xXPatients with preexisting peripheral neuropathy >= grade 2 are ineligibleXx_NEWLINE_xXPatients with grade >= 2 peripheral neuropathyXx_NEWLINE_xXFor the bortezomib arm of the study, patients with grade >= 2 peripheral neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy, or grade 1 with pain on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathy > grade 1Xx_NEWLINE_xXPatients with peripheral neuropathy greater than grade IIXx_NEWLINE_xXPatients with grade 2 or higher peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 1Xx_NEWLINE_xXPre-existing peripheral neuropathy CTCAE grade 2 or worseXx_NEWLINE_xXNeuropathy > Grade 1Xx_NEWLINE_xXHas > Grade 1 peripheral sensory neuropathy or > Grade 1 peripheral motor neuropathy graded according to the Modified (\Balis\) Pediatric Scale of Peripheral NeuropathiesXx_NEWLINE_xXparticipants with Grade 2 or higher residual toxicities from prior therapy (including Grade 2 or higher peripheral neuropathy or any grade neuropathy with pain; excluding alopecia). This includes recovery from any major surgery. Note: Participants with planned surgical to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.Xx_NEWLINE_xXPeripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening periodXx_NEWLINE_xXHas greater than or equal to (>=) Grade 2 peripheral neuropathy, or Grade 1 with pain on clinical examination during the screening period.Xx_NEWLINE_xXToxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathyXx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to randomizationXx_NEWLINE_xXHas history of Grade 2 or greater peripheral neuropathy during the 3 months prior to enrollment.Xx_NEWLINE_xXPatient has peripheral neuropathy of Grade 3 or greater intensity, or painful Grade 2, as defined by the NCI CTC.Xx_NEWLINE_xXResolution of any toxic effects of prior therapy to Grade ?1 according to NCI CTCAE, version 4.0 (exception of alopecia and ? Grade 2 peripheral neuropathy).Xx_NEWLINE_xXPatient with peripheral neuropathy Grade >2Xx_NEWLINE_xXPresence of neuropathy > Grade 1 (NCI CTC, Version 4.0)Xx_NEWLINE_xXPresence of neuropathy > Grade 1 (NCI CTC, Version 4.0)Xx_NEWLINE_xXGrade 2 or higher persisting prior treatment-related neuropathyXx_NEWLINE_xXPatients with grade 2 or greater peripheral neuropathy.Xx_NEWLINE_xXCTCAE v4 Grade ?2 peripheral neuropathyXx_NEWLINE_xXGrade 2 or higher peripheral neuropathyXx_NEWLINE_xXNeuropathy (?grade 2 CTCAE)Xx_NEWLINE_xXGrade II or greater neuropathy at baselineXx_NEWLINE_xXPeripheral neuropathy >= grade 2 or clinically significant sensorineural hearing loss or tinnitusXx_NEWLINE_xXPaclitaxel arm: grade 2 or higher neuropathyXx_NEWLINE_xXPatient has ? grade 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination during the screening periodXx_NEWLINE_xXCurrent peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndromeXx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXPreexisting peripheral neuropathy is not allowed from any causeXx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXPre-existing peripheral neuropathy grade ?= 2 at registrationXx_NEWLINE_xXPatients with >= grade 2 neuropathyXx_NEWLINE_xXNo grade >= 2 neuropathyXx_NEWLINE_xXOngoing grade >= 3 neuropathyXx_NEWLINE_xXGrade 2 or higher peripheral neuropathy.Xx_NEWLINE_xX>= grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2 despite supportive therapyXx_NEWLINE_xXCentral nervous system (CNS) toxicity including peripheral neuropathy =< grade 2Xx_NEWLINE_xXSubjects with grade 2 or greater neuropathyXx_NEWLINE_xXPeripheral neuropathy of severity greater than grade 1Xx_NEWLINE_xXMotor peripheral neuropathy = grade 0 (per CTCAE v. 4.0)Xx_NEWLINE_xXGrade 2 or higher peripheral neuropathy per NCI CTCAEXx_NEWLINE_xXGreater than grade 1 peripheral neuropathy at baselineXx_NEWLINE_xXPeripheral neuropathy >= grade 3 on clinical examination or grade 2 with pain during the screening periodXx_NEWLINE_xXPatients with existing grade 3 or 4 peripheral neuropathyXx_NEWLINE_xXBaseline neuropathy > grade 1Xx_NEWLINE_xXPeripheral neuropathy >= grade 2 at baseline OR peripheral neuropathy >= grade I with neuropathic painXx_NEWLINE_xXPatients with grade 3/4 peripheral neuropathyXx_NEWLINE_xXPatients who have baseline peripheral neuropathy >= grade 2 are not eligibleXx_NEWLINE_xXPatient has baseline neuropathy of > grade 2Xx_NEWLINE_xXGrade > 2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1)Xx_NEWLINE_xXSubject has >= grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXGrade 2 or higher peripheral neuropathyXx_NEWLINE_xXPatients with > grade 1 peripheral sensory neuropathy or > grade 1 peripheral motor neuropathy graded according to the Modified (“Balis”) Pediatric Scale of Peripheral Neuropathies are not eligibleXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days of trial enrollmentXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or >= grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPre-existing grade 2 or greater neuropathyXx_NEWLINE_xXGrade 2 or greater neuropathyXx_NEWLINE_xXPre-existing peripheral neuropathy > grade 2 with pain (CTC version 4.0).Xx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXPeripheral neuropathy =< grade 1Xx_NEWLINE_xX>= grade 2 peripheral neuropathyXx_NEWLINE_xX>= grade 2 peripheral neuropathy within 14 days before beginning maintenance therapyXx_NEWLINE_xXPre-existing grade >= 1 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapyXx_NEWLINE_xXPatients with >= grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy grade 2 or greaterXx_NEWLINE_xXPatients must not have grade 2 or higher peripheral neuropathyXx_NEWLINE_xXPatients must not have peripheral neuropathy >= grade 2Xx_NEWLINE_xXPatients with peripheral neuropathy > grade 2 regardless of etiologyXx_NEWLINE_xXAny unresolved toxicity ? Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapyXx_NEWLINE_xXHas peripheral neuropathy ? Grade 2.Xx_NEWLINE_xXPeripheral neuropathy >= grade 2 on clinical examination, within 21 days of initiation of protocol therapyXx_NEWLINE_xXPeripheral neuropathy =< grade 1Xx_NEWLINE_xXNeuropathy Grade > 3Xx_NEWLINE_xXHas peripheral neuropathy ? Grade 2Xx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to 1 or returned to baseline except alopecia (any grade) and Grade 2 peripheral neuropathyXx_NEWLINE_xXGrade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy [Applies to Phase 2].Xx_NEWLINE_xXSubjects with baseline peripheral neuropathy that exceeds grade 1Xx_NEWLINE_xXSignificant symptoms (grade >= 2) peripheral neuropathyXx_NEWLINE_xXPre-existing neuropathy of at least Grade 2Xx_NEWLINE_xXPeripheral neuropathy ? Grade 3 or ? Grade 2 with pain within 2 weeks prior to first doseXx_NEWLINE_xXPeripheral neuropathy ? Grade 2Xx_NEWLINE_xXPeripheral neuropathy ? Grade 2.Xx_NEWLINE_xXHas peripheral neuropathy ? Grade 2Xx_NEWLINE_xXPatients who have had grade 2 or higher peripheral neuropathy within 14 days prior to registration are not eligible (must have resolved to grade 1 or lower to register)Xx_NEWLINE_xXPeripheral neuropathy or neuropathic pain Grade 2 or higherXx_NEWLINE_xXCurrent Grade >1 peripheral neuropathyXx_NEWLINE_xXNeuropathy >NCI-CTCAE Grade 1.Xx_NEWLINE_xXGrade <= 2 neuropathyXx_NEWLINE_xXGrade ? 2 peripheral neuropathyXx_NEWLINE_xXNeuropathy uropathy europathy Nemediastinal DLBCL.Xx_NEWLINE_xXNeurosensory neuropathy ? grade 2 at baseline.Xx_NEWLINE_xXLess than Grade 2 pre-existing peripheral neuropathyXx_NEWLINE_xXNeuropathy CTCAE grade > 2Xx_NEWLINE_xXPre-existing neuropathy from any cause in excess of Grade 1.Xx_NEWLINE_xXEqual to or greater than grade 2 ataxia, cranial or peripheral neuropathyXx_NEWLINE_xXPatients with > grade 1 neuropathyXx_NEWLINE_xXPeripheral neuropathy < grade 2Xx_NEWLINE_xXSubjects with >= grade 2 neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days before enrollment and at D60-180 after AHCT; patients who had >= grade 2 peripheral neuropathy within 14 days before enrollment but resolves to grade 1 or lower peripheral neuropathy at D60-D180 after AHCT can be enrolled at this timeXx_NEWLINE_xXPre-existing peripheral neuropathy >= Common Terminology Criteria (CTC) grade 2 for those patients who received prior paclitaxelXx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXCurrent Grade >1 peripheral neuropathy from any causeXx_NEWLINE_xXEvidence of ? Grade 2 neuropathyXx_NEWLINE_xXPatients must not have peripheral neuropathy > grade 2Xx_NEWLINE_xXPeripheral neuropathy exclusionsXx_NEWLINE_xXNeuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0Xx_NEWLINE_xX? Grade 2 peripheral neuropathyXx_NEWLINE_xXBaseline peripheral neuropathy/paresthesia grade >= 1Xx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathyXx_NEWLINE_xXNeuropathy > Grade 1.Xx_NEWLINE_xXPatients with symptomatic neuropathyXx_NEWLINE_xXPatients with >= grade 2 neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathyXx_NEWLINE_xXGrade 2 or greater neuropathyXx_NEWLINE_xXPatients must not have grade 2 or greater peripheral neuropathyXx_NEWLINE_xXSerious peripheral neuropathy.Xx_NEWLINE_xXUncontrolled neuropathy grade 2 or greater regardless of cause.Xx_NEWLINE_xXPersisting ?Grade 2 CTCAE toxicity (except alopecia and Grade 2 peripheral neuropathy) from previous anti-cancer treatment(s)Xx_NEWLINE_xXPeripheral neuropathy- grade 2 or greaterXx_NEWLINE_xXPeripheral neuropathy ? Grade 2.Xx_NEWLINE_xXPatients must have < Grade 2 or pre-existing neuropathy (per CTCAE).Xx_NEWLINE_xXPeripheral neuropathy grade 2 or greaterXx_NEWLINE_xXResolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =<1 prior to first study treatment (with the exception of alopecia or neuropathy; chemotherapy-induced peripheral neuropathy up to grade =< 2 will be permitted)Xx_NEWLINE_xXPre-existing Grade greater than (>) 1 neuropathyXx_NEWLINE_xXPatient has >= grade 1 peripheral neuropathy with pain on clinical examination during the screening periodXx_NEWLINE_xXPrevious diagnosis of diabetic neuropathy or peripheral neuropathy from any causeXx_NEWLINE_xXParticipants who have more than grade 1 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXNeuropathy grade 2 or higherXx_NEWLINE_xXPeripheral neuropathy < grade 2Xx_NEWLINE_xXSignificant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXSignificant neuropathy (? Grade 3) within the 14 days prior to randomizationXx_NEWLINE_xXClinically significant peripheral neuropathyXx_NEWLINE_xXHas baseline peripheral neuropathy/paresthesia grade ? 1.Xx_NEWLINE_xXParticipant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapyXx_NEWLINE_xXEvidence of peripheral neuropathy of Grade >2.Xx_NEWLINE_xXGrade 2 or higher peripheral neuropathy (paclitaxel arm only)Xx_NEWLINE_xXPre-existing peripheral neuropathy (grade I or higher)Xx_NEWLINE_xXPatients with grade 2 peripheral neuropathy or greater are excludedXx_NEWLINE_xXPatients with Grade 2 or greater pre-existing neurologic abnormalities (CTCAE version 4.0), including Grade 2 or greater peripheral neuropathy caused by previous treatments.Xx_NEWLINE_xXSignificant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXSubjects with >= grade 2 neuropathyXx_NEWLINE_xXSubject has peripheral neuropathy ? grade 2.Xx_NEWLINE_xXPeripheral neuropathy >= grade 1Xx_NEWLINE_xXEqual to or greater than grade 2 ataxia, cranial or peripheral neuropathyXx_NEWLINE_xXGrade 3 or above peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy: must be =< grade 1Xx_NEWLINE_xXGrade > 2 peripheral neuropathy at baselineXx_NEWLINE_xXGrade >= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXPatients with existing peripheral neuropathy grade > 2Xx_NEWLINE_xXPeripheral neuropathy =< grade 1 at the time of registrationXx_NEWLINE_xXThe patient has peripheral neuropathy >= grade 2Xx_NEWLINE_xXPatients with grade II or greater peripheral neuropathy will be excluded from studyXx_NEWLINE_xXGrade >= 2 peripheral neuropathy within 14 days prior to initiation of therapyXx_NEWLINE_xXPatient has > grade 2 peripheral neuropathy on clinical examination during the screening periodXx_NEWLINE_xXSubject has peripheral neuropathy >= grade 2.Xx_NEWLINE_xXGrade 2 or higher neuropathy (CTCAE V4.0)Xx_NEWLINE_xXPresence of peripheral neuropathy ? CTCAE Grade 2Xx_NEWLINE_xXSignificant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to the first day of treatmentXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXNeurosensory neuropathy ? grade 2 at baselineXx_NEWLINE_xXPeripheral neuropathy ? Grade 2 despite supportive therapyXx_NEWLINE_xXParticipant has >= grade 2 peripheral neuropathy on clinical examination within 21 days before initiation of protocol therapyXx_NEWLINE_xXSignificant neuropathy >= grade 3 or grade 2 neuropathy with pain at baselineXx_NEWLINE_xXHas baseline peripheral neuropathy/paresthesiaXx_NEWLINE_xXCOHORT II: Patients must not have >= grade 2 peripheral neuropathyXx_NEWLINE_xXSignificant neuropathy >= grade 3 or grade 2 neuropathy with pain at baselineXx_NEWLINE_xXSignificant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to signing consentXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXSignificant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of first doseXx_NEWLINE_xX> Grade 3 neuropathyXx_NEWLINE_xXPeripheral neuropathy > Grade 2.Xx_NEWLINE_xXCurrent grade II or higher peripheral neuropathy.Xx_NEWLINE_xXSignificant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first doseXx_NEWLINE_xXSubjects with pre-existing grade 3 or 4 neuropathy; any peripheral neuropathy must recover to grade =< 1 before enrollmentXx_NEWLINE_xXSignificant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollmentXx_NEWLINE_xXCurrent NCI CTCAE (Version 4.0) Grade >/= 2 peripheral neuropathyXx_NEWLINE_xXGrade >= 2 peripheral neuropathy within 21 days before enrollmentXx_NEWLINE_xXPeripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization.Xx_NEWLINE_xXSignificant neuropathy (grades 3-4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPre-existing neuropathy greater than grade 1Xx_NEWLINE_xXPatients with greater than or equal to grade 2 peripheral neuropathy at baselineXx_NEWLINE_xXPatient must not have >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathyXx_NEWLINE_xXPre-existing neuropathy greater than grade 1.Xx_NEWLINE_xXPre-existing neuropathy grade III or greaterXx_NEWLINE_xXNeuropathy, grade 2 or greater by NCI-CTCAE, v. 4.0Xx_NEWLINE_xXGrade >1 neuropathyXx_NEWLINE_xXPeripheral neuropathy greater than Grade 1Xx_NEWLINE_xXPeripheral neuropathy >= grade 2 at baseline OR peripheral neuropathy >= grade I with neuropathic painXx_NEWLINE_xXPre-existing neuropathy from any cause in excess of Grade 1Xx_NEWLINE_xXNo peripheral neuropathy greater than grade 1, due to any causeXx_NEWLINE_xXPatient has >= grade 2 (CTCAE v 4.0) peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXHistory of Grade ?2 neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy on clinical examination within 28 days of signing consentXx_NEWLINE_xXPeripheral neuropathy: must be =< grade 1Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXGrade 2 or more peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy of grade >=3. Patients with painful grade 2 neuropathy are also excludedXx_NEWLINE_xXPeripheral neuropathy ? Grade 2Xx_NEWLINE_xXPatient has baseline neuropathy of >= grade 2Xx_NEWLINE_xXPeripheral neuropathy >= grade 3Xx_NEWLINE_xXSignificant peripheral neuropathy defined as grade 2 or higherXx_NEWLINE_xXNo ? grade 2 peripheral neuropathy.Xx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXNeuropathy > grade 2Xx_NEWLINE_xXPatient has > = Grade 2 peripheral neuropathy within 14 days before enrollment.Xx_NEWLINE_xXCTCAE version 4.03 > grade 3 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy =< grade 1Xx_NEWLINE_xXSignificant neuropathy >= grade 3 or grade 2 neuropathy with pain at baselineXx_NEWLINE_xXPatient has grade 3 peripheral neuropathy or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPre-existing peripheral neuropathy >= grade 2Xx_NEWLINE_xXPeripheral neuropathy >= grade (Gr) IIXx_NEWLINE_xXSubject has > grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xX? Grade-2 neuropathyXx_NEWLINE_xXGrade >= 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXPeripheral neuropathy =< grade 1Xx_NEWLINE_xXPeripheral neuropathy >/= Grade 2 (NCI-CTC Version 3.0)Xx_NEWLINE_xXPatient has >/= Grade 2 peripheral neuropathy within 14 days before enrollment.Xx_NEWLINE_xXNo grade 2 >= peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXGrade 3 peripheral neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathyXx_NEWLINE_xXPatients with peripheral neuropathy of grade >= 3; patients with painful grade 2 neuropathy are also excludedXx_NEWLINE_xXHas peripheral neuropathy ? Grade 2 (NCI-CTCAE)Xx_NEWLINE_xXNo current grade 2, 3, or 4 of neuropathyXx_NEWLINE_xXPeripheral neuropathyXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 peripheral neuropathy with pain on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathy > grade 2Xx_NEWLINE_xXCurrent grade II or higher peripheral neuropathy.Xx_NEWLINE_xXPeripheral neuropathy that is grade 2 or higherXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade </= 1, except alopecia (any grade) and Grade 2 peripheral neuropathyXx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xX> grade 2 peripheral neuropathy at baselineXx_NEWLINE_xXPeripheral neuropathy of grade 2 or greaterXx_NEWLINE_xXPresence of ? Grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy ? Grade 3.Xx_NEWLINE_xXPresence of clinically significant non-hematological toxicity of prior chemotherapy that has not resolved to ? Grade 1 as determined by CTCAE v 4.0, with the exception of alopecia and peripheral neuropathy. Note: Peripheral neuropathy > Grade 2 plus pain, or Grade 3 or Grade 4 are excluded.Xx_NEWLINE_xXPresence of > Grade 1 peripheral neuropathyXx_NEWLINE_xXSigns of peripheral neuropathy (PN) ? NCI CTCAE Grade 2.Xx_NEWLINE_xXSigns of peripheral neuropathy (PN) ? NCI CTCAE Grade 2.Xx_NEWLINE_xXGrade 3 or higher peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy CTCAE Grade ?2Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathy ? Grade 2Xx_NEWLINE_xXPatients with any neuropathy > Grade 1Xx_NEWLINE_xXPatients with grade > 2 neuropathy attributable to previous administration of taxane chemotherapyXx_NEWLINE_xXGrade 2 or higher peripheral neuropathy per NCI CTCAEXx_NEWLINE_xXSignificant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXhave persistent Grade 2 or greater toxicities from any cause (except alopecia or peripheral neuropathy).Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screeningXx_NEWLINE_xXPeripheral edema > grade 1Xx_NEWLINE_xXPatients with peripheral neuropathy > 2Xx_NEWLINE_xXBaseline peripheral neuropathy ? grade 2.Xx_NEWLINE_xXClinical evidence of neuropathyXx_NEWLINE_xXPeripheral neuropathy ? grade 2.Xx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXIf applicable, patient has >= Grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXSignificant neuropathy >= grade 3 at baselineXx_NEWLINE_xXPeripheral neuropathy greater than grade 1Xx_NEWLINE_xXPatients with grade >= 2 peripheral neuropathy will not be permitted on studyXx_NEWLINE_xXAny peripheral neuropathy ? NCI CTCAE Grade 2.Xx_NEWLINE_xXPatients with any neuropathy.Xx_NEWLINE_xXPatients with preexisting peripheral neuropathy grade >= 2 will not be eligibleXx_NEWLINE_xXEvidence of peripheral neuropathy of Grade > 2Xx_NEWLINE_xXSubjects with > grade 1 peripheral neuropathyXx_NEWLINE_xXPatients with > grade 2 neuropathy according to the Modified (“Balis”) Pediatric Scale of Peripheral Neuropathies will be excluded except in cases in which neuropathy is secondary to prior surgeryXx_NEWLINE_xXPatients with neuropathy > grade 1Xx_NEWLINE_xXSignificant neurotoxicity/neuropathy (Grade 3 or higher) within 14 days prior to Day 1Xx_NEWLINE_xXPeripheral neuropathy Grade >/=2Xx_NEWLINE_xXSubjects with preexisting Grade 3 or 4 neuropathy. Any peripheral neuropathy must recover to Grade less than or equal to 2 before enrollmentXx_NEWLINE_xXGrade 2 or higher neuropathyXx_NEWLINE_xXPresence of peripheral neuropathyXx_NEWLINE_xXSubject has Neuropathy ? Grade 2 at Screening.Xx_NEWLINE_xXSymptomatic peripheral neuropathy grade ?2 NCI CTCAE v4.0.Xx_NEWLINE_xXSubjects with Grade >2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy at study entryXx_NEWLINE_xX>= grade 2 pre-existing peripheral neuropathy (per CTCAEv4)Xx_NEWLINE_xXPeripheral neuropathy CTCAE v4.03 Grade ? 3Xx_NEWLINE_xXPatients with peripheral neuropathy >= grade 2Xx_NEWLINE_xXPatients with greater than 2 screening peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy ? CTCAE Grade 2 at baseline.Xx_NEWLINE_xXPatients who have grade >= 2 peripheral neuropathyXx_NEWLINE_xXPreexisting grade >= 2 peripheral neuropathyXx_NEWLINE_xXPatients with peripheral neuropathy >= grade 2 are not permitted unless discussed with the principal investigator and only in unique circumstances (i.e. unilateral neuropathy due to trauma)Xx_NEWLINE_xXWith < or = grade 2 neuropathyXx_NEWLINE_xX> grade 2 neuropathyXx_NEWLINE_xXCurrent grade 3 or higher neuropathyXx_NEWLINE_xXGrade 2 or higher peripheral neuropathyXx_NEWLINE_xXOngoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy with pain despite appropriate interventions, within 28 days prior to first dose of study treatment.Xx_NEWLINE_xXPatients with grade III-IV neuropathyXx_NEWLINE_xXSignificant neuropathy (grades 3 to 4, or grade 2 pain)Xx_NEWLINE_xXNo grade >= 2 peripheral neuropathyXx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathyXx_NEWLINE_xXSignificant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to randomizationXx_NEWLINE_xXGrade 2 or above neuropathyXx_NEWLINE_xXGrade >=2 peripheral neuropathyXx_NEWLINE_xXPresence of ? Grade 2 neuropathy.Xx_NEWLINE_xXBaseline peripheral edema >= grade 3Xx_NEWLINE_xXPre-existing peripheral neuropathy grade >= 2Xx_NEWLINE_xXNeuropathy Grade 3 or moreXx_NEWLINE_xXPart 2 only: Patients with >= grade 2 peripheral neuropathy.Xx_NEWLINE_xXIf applicable, patient has >= grade 2 peripheral neuropathy within 14 days before enrollmentXx_NEWLINE_xXSignificant peripheral neuropathy (Grade 3, Grade 4, or Grade 2 with pain) within 14 days prior to first doseXx_NEWLINE_xXGrade 2 or higher peripheral neuropathy at the time of study entryXx_NEWLINE_xXPeripheral neuropathy ?Grade 2.Xx_NEWLINE_xXSignificant neuropathy (grades 3–4, or grade 2 with pain) within 14 days prior to randomizationXx_NEWLINE_xX>= grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2 on clinical examination during the screening periodXx_NEWLINE_xXPeripheral neuropathyXx_NEWLINE_xXSignificant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the first dose and/or within 14 days before study treatmentXx_NEWLINE_xXPatients with a >= grade 2 peripheral neuropathyXx_NEWLINE_xXCurrent Grade >1 peripheral neuropathyXx_NEWLINE_xXHistory of peripheral neuropathy; (note: this does not apply to Cohort 3)Xx_NEWLINE_xXUnresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade 1 peripheral neuropathyXx_NEWLINE_xXGrade >=2 peripheral neuropathyXx_NEWLINE_xXPatients with peripheral neuropathy >= grade 2Xx_NEWLINE_xXGrade ?2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1).Xx_NEWLINE_xXSignificant neuropathy (Grades 3 to 4, or Grade 2 with pain) within 14 days prior to randomization.Xx_NEWLINE_xXCurrent peripheral neuropathy of NCI-CTC, version 4.0 Grade 3 or greaterXx_NEWLINE_xXGrade 2 or greater peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy >= grade 2Xx_NEWLINE_xXPatient has >= grade 2 peripheral neuropathy within 14 days prior to treatment initiationXx_NEWLINE_xXPeripheral neuropathy that is greater or equal to Grade 2Xx_NEWLINE_xXHas peripheral neuropathy that is greater or equal to Grade 2Xx_NEWLINE_xXPre-existing peripheral neuropathy greater than CTCAE Grade 2.Xx_NEWLINE_xXPatient has > Grade 2 painful neuropathy or peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy ? Grade 2Xx_NEWLINE_xXPatients with peripheral neuropathy > grade 1 will be excluded from study participationXx_NEWLINE_xXThe participant has any Grade 2 (or greater) peripheral neuropathy.Xx_NEWLINE_xXPre-existing >= grade 2 peripheral neuropathyXx_NEWLINE_xXSignificant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomizationXx_NEWLINE_xXNo grade 2 or greater peripheral neuropathy.Xx_NEWLINE_xXGrade >= 2 neuropathyXx_NEWLINE_xXHistory of peripheral neuropathy of ?grade 2Xx_NEWLINE_xXPatients with symptomatic peripheral neuropathy> Grade 1.Xx_NEWLINE_xXPeripheral neuropathy > grade 1 (NCI-CTC).Xx_NEWLINE_xXPeripheral neuropathy of > grade 2 severity.Xx_NEWLINE_xXPeripheral neuropathy ? CTCAE grade 2Xx_NEWLINE_xXPeripheral neuropathy with grade =< 1Xx_NEWLINE_xXNeuropathy >= grade 2 (moderate neuropathy that limits instrumental activities of daily living)Xx_NEWLINE_xXClinically significant (>= grade 2) peripheral neuropathy at the time of study entryXx_NEWLINE_xXSubject has ? CTCAE v4.03 Grade 2 neuropathy.Xx_NEWLINE_xXSignificant neuropathy (grades 3 - 4, or grade 2 with pain) within 14 days prior to enrollmentXx_NEWLINE_xXPatient has pre-existing peripheral neuropathy Grade >1Xx_NEWLINE_xXPeripheral neuropathy >= grade 1Xx_NEWLINE_xXGrade >= 2 peripheral neuropathyXx_NEWLINE_xXPatients must not have a history of peripheral neuropathy (regardless of cause)Xx_NEWLINE_xXPre-existing symmetric peripheral painful neuropathyXx_NEWLINE_xXAny peripheral neuropathy >= grade 3Xx_NEWLINE_xXPatients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapyXx_NEWLINE_xXGrade III or IV upper extremity peripheral neuropathyXx_NEWLINE_xXSelf-report of >= 4 on the Peripheral Neuropathy QuestionXx_NEWLINE_xXPresence of pain primarily due to chemotherapy induced peripheral neuropathyXx_NEWLINE_xXPatients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy.Xx_NEWLINE_xXHistory of peripheral neuropathy prior to receiving neurotoxic chemotherapyXx_NEWLINE_xXPain or symptoms of peripheral neuropathy of > 3 month's duration attributed to chemotherapy-induced peripheral neuropathyXx_NEWLINE_xXSCREENING PHASE: Pre-existing peripheral neuropathy within 28 days of screening consentXx_NEWLINE_xXINTERVENTION PHASE: Pre-existing peripheral neuropathy within 28 days of screening consentXx_NEWLINE_xXPrevious diagnosis of diabetic neuropathy or peripheral neuropathy from any causeXx_NEWLINE_xXPre-existing grade 2 or greater neuropathyXx_NEWLINE_xXNeuropathy: no baseline neuropathy grade > 2Xx_NEWLINE_xXPeripheral neuropathy greater than or equal to grade 2.Xx_NEWLINE_xXHistory of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, human immunodeficiency virus (HIV), congenital neuropathy, toxic neuropathyXx_NEWLINE_xXPatient with >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXGrade 2 or higher peripheral neuropathyXx_NEWLINE_xXGrade II or higher neuropathyXx_NEWLINE_xXNo >= grade 2 peripheral neuropathyXx_NEWLINE_xXPeripheral neuropathy ? grade 2Xx_NEWLINE_xXPeripheral neuropathy greater than grade 1Xx_NEWLINE_xXHave pre-existing peripheral neuropathy from other medical conditions or due to cancerXx_NEWLINE_xXGreater than Grade 2 neuropathy or ? Grade 2 neuropathy with pain at baseline, regardless of whether or not the patient is currently receiving medicationXx_NEWLINE_xXPeripheral neuropathy greater than grade 1Xx_NEWLINE_xXPatient has >= grade 3 peripheral neuropathy, or grade 2 with pain on clinical examination during the screening periodXx_NEWLINE_xXAll acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade less than or equal to (<=) 1 or returned to baseline, except alopecia (any grade) and Grade 2 peripheral neuropathyXx_NEWLINE_xXNeuropathy with or without painXx_NEWLINE_xXHas neuropathy ? Grade 2.Xx_NEWLINE_xX